Global Neuroprotection Drugs Market By Drugs Type (Antidepressants, Antiepileptic, Antipsychotic, Anti-inflammatory, Anesthetics, Antagonists, Antibiotics, Antidepressants, Antioxidants, Cytokines, Ion Channel Blockers, Neurosteroids, Nutraceuticals, Pathway Inhibitors and Others (Vaccines, Toxins, etc.)), By Application (Cerebrovascular Disease (Ischemic Stroke, Hemorrhagic Stroke, cerebrovascular anomalies(intracranial aneurysms and arteriovenous malformations), Neurodegenerative Disorders (Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis, Progressive supranuclear palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Dementia With Lewy Bodies (DLB) Others (Multiple System Atrophy (MSA), Chronic Traumatic Encephalopathy (CTE), Etc.), Traumatic CNS Injuries (Coup-Contrecoup Brain Injury, Concussion, Brain Concussion, Diffuse Axonal Injury, Penetrating Injury, Second Impact Syndrome, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Report ID :AMI-229 | Category : Healthcare | Published Date : July, 2019 | Pages : 211 | Format :PDF